We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Production of the antimalarial drug precursor artemisinic acid in engineered yeast.
- Authors
Dae-Kyun Ro; Paradise, Eric M.; Ouellet, Mario; Fisher, Karl J.; Newman, Karyn L.; Ndungu, John M.; Ho, Kimberly A.; Eachus, Rachel A.; Ham, Timothy S.; Kirby, James; Chang, Michelle C. Y.; Withers, Sydnor T.; Shiba, Yoichiro; Sarpong, Richmond; Keasling, Jay D.
- Abstract
Malaria is a global health problem that threatens 300–500 million people and kills more than one million people annually. Disease control is hampered by the occurrence of multi-drug-resistant strains of the malaria parasite Plasmodium falciparum. Synthetic antimalarial drugs and malarial vaccines are currently being developed, but their efficacy against malaria awaits rigorous clinical testing. Artemisinin, a sesquiterpene lactone endoperoxide extracted from Artemisia annua L (family Asteraceae; commonly known as sweet wormwood), is highly effective against multi-drug-resistant Plasmodium spp., but is in short supply and unaffordable to most malaria sufferers. Although total synthesis of artemisinin is difficult and costly, the semi-synthesis of artemisinin or any derivative from microbially sourced artemisinic acid, its immediate precursor, could be a cost-effective, environmentally friendly, high-quality and reliable source of artemisinin. Here we report the engineering of Saccharomyces cerevisiae to produce high titres (up to 100 mg l-1) of artemisinic acid using an engineered mevalonate pathway, amorphadiene synthase, and a novel cytochrome P450 monooxygenase (CYP71AV1) from A. annua that performs a three-step oxidation of amorpha-4,11-diene to artemisinic acid. The synthesized artemisinic acid is transported out and retained on the outside of the engineered yeast, meaning that a simple and inexpensive purification process can be used to obtain the desired product. Although the engineered yeast is already capable of producing artemisinic acid at a significantly higher specific productivity than A. annua, yield optimization and industrial scale-up will be required to raise artemisinic acid production to a level high enough to reduce artemisinin combination therapies to significantly below their current prices.
- Publication
Nature, 2006, Vol 440, Issue 7086, p940
- ISSN
0028-0836
- Publication type
Academic Journal
- DOI
10.1038/nature04640